Skip to content

Research at St Andrews

Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease

Research output: Contribution to journalArticle


David McGhee, Alexander Parker, Shona Fielding, John Zajicek, Carl Counsell

School/Research organisations


BACKGROUND: Simple, robust, sensitive and clinically meaningful outcome measures are required for neuroprotective trials in Parkinson's disease (PD). We explored the feasibility of a composite binary outcome measure, 'dead or dependent', in such trials using data from a prospective follow-up study of an incident cohort of PD patients.

METHODS: Two hundred incident patients had an annual follow-up, including assessment of the Hoehn-Yahr stage (H-Y) and Schwab and England Activities of Daily Living Scale (S&E). Annual scores were converted into binary variables (H-Y <3 vs H-Y ≥3, and S&E ≥80% vs S&E <80%). A new outcome of 'dead or dependent' was also created, with dependence in activities of daily living defined as S&E <80%. Using these data, sample sizes were calculated for a hypothetical three-year randomised trial in which the trial outcome was defined by a binary clinical variable, all-cause mortality, or PD-related mortality.

RESULTS: At 3 years, 18.0% of patients were dead and 38.4% were dead or dependent. At 80% power, large sample sizes were required if PD-related mortality (n=1938 per study arm) or all-cause mortality (n=734) were used as the outcome, even for large treatment effects (30% reduction in relative risk). The new outcome of 'death or dependency' required the smallest sample sizes of all the outcome measures (n=277 for 30% reduction in relative risk, 627 for a 20% reduction).

CONCLUSIONS: 'Death or dependency' is a feasible and potentially useful outcome measure in PD trials of neuroprotective agents, but further work is required to validate its use and define dependency.



Original languageEnglish
Pages (from-to)180-185
Number of pages6
JournalJournal of Neurology, Neurosurgery, and Psychiatry
Issue number2
Early online date22 May 2014
Publication statusPublished - Feb 2015

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis

    Freeman, J. A., Hendrie, W., Jarrett, L., Hawton, A., Barton, A., Dennett, R., Jones, B., Zajicek, J. P. & Creanor, S., 1 Aug 2019, In : Lancet Neurology. 18, 8, p. 736-747

    Research output: Contribution to journalArticle

  2. Machine-learning based identification of undiagnosed dementia in primary care: a feasibility study

    Jammeh, E. A., Carroll, C. B., Pearson, S. W., Escudero, J., Anastasiou, A., Zhao, P., Chenore, T., Zajicek, J. & Ifeachor, E., 12 Jun 2018, In : BJGP Open. 2, 2, 13 p., bjgpopen18X101589.

    Research output: Contribution to journalArticle

  3. Improving the quality of cognitive screening assessments: ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-III

    Newman, C. G. J., Bevins, A. D., Zajicek, J. P., Hodges, J. R., Vuillermoz, E., Dickenson, J. M., Kelly, D. S., Brown, S. & Noad, R. F., 2018, In : Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 10, p. 182-187 6 p.

    Research output: Contribution to journalArticle

  4. Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial

    Gunn, H., Andrade, J., Paul, L., Miller, L., Creanor, S., Green, C., Marsden, J., Ewings, P., Berrow, M., Vickery, J., Barton, A., Marshall, B., Zajicek, J. & Freeman, J. A., 27 Jul 2017, In : Pilot and Feasibility Studies. 4, 12 p., 26.

    Research output: Contribution to journalArticle

  5. Time-and region-specific season of birth effects in multiple sclerosis in the United Kingdom

    Cruz, P. M. R., Matthews, L., Boggild, M., Cavey, A., Constantinescu, C. S., Evangelou, N., Giovannoni, G., Gray, O., Hawkins, S., Nicholas, R., Oppenheimer, M., Robertson, N., Zajicek, J., Rothwell, P. M. & Palace, J., 1 Aug 2016, In : JAMA Neurology. 73, 8, p. 954-960 7 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Short-interval observational data to inform clinical trial design in early Huntington’s Disease

    Hobbs, N. Z., Farmer, R. E., Rees, E. M., Cole, J. H., Haider, S., Malone, I. B., Sprengelmeyer, R. H., Johnson, H., Mueller, H-P., Sussmuth, S. D., Roos, R. A. C., Durr, A., Frost, C., Scahill, R. I., Landwehrmeyer, B. & Tabrizi, S. J., 2015, In : Journal of Neurology, Neurosurgery, and Psychiatry.

    Research output: Contribution to journalArticle

  2. Multiple sclerosis and extract of cannabis: results of the MUSEC trial

    Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., Mattison, P. G. & MUSEC Research Group, Nov 2012, In : Journal of Neurology, Neurosurgery, and Psychiatry. 83, 11, p. 1125-32 8 p.

    Research output: Contribution to journalArticle

  3. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

    Zajicek, J. P., Sanders, H. P., Wright, D. E., Vickery, P. J., Ingram, W. M., Reilly, S. M., Nunn, A. J., Teare, L. J., Fox, P. J. & Thompson, A. J., Dec 2005, In : Journal of Neurology, Neurosurgery, and Psychiatry. 76, 12, p. 1664-9 6 p.

    Research output: Contribution to journalArticle

  4. Facial expression recognition and subthalamic nucleus stimulation

    Schroeder, U., Kuehler, A., Hennenlotter, A., Haslinger, B., Tronnier, VM., Krause, R., Pfister, R., Sprengelmeyer, R. H., Lange, KW. & Ceballos-Baumann, AO., 1 Apr 2004, In : Journal of Neurology, Neurosurgery, and Psychiatry. 75, p. 648-650 3 p.

    Research output: Contribution to journalArticle

ID: 242546265